IVDT_In Vitro Diagnostics Technology

IVD Technology, November/December 2012

Issue link: http://dc.cn.ubm-us.com/i/92152

Contents of this Issue

Navigation

Page 21 of 43

MOLECULAR DIAGNOSTICS F mec mec SHo Efa SA/ SW SGe Slu MRSA S. aureus S. warnerineat S. warneri- 1/100 S. lugdunensis- 1/100 Saur Sep HC Sca F SPC SPC DC Figure 5. Representative results for the detection of bacterial species using Staph ID/R. Blood cultures positive for the indicated bacterial species were tested using the Staph ID/R protocol, and CCD images of resulting chips are shown. Probe map is shown in right panel. F = fi ducial marker, DC = detect control, HC = hybridization control, SGe = Staphylococ- cus genus, SA = S. aureus, SE = S. epidermidis, SHa = S. haemolyticus, Sca = S. capitis, Slu = S. lugdunensis, SHo = S. hominis, SW = S. warneri, EFa = E. faecalis, mec = mecA. ment of bloodstream infections has been associated with improved patient outcomes, and clinical-outcome studies have shown that reducing the time to diagnosis decreases the patient's length coagulase-negative staphylococci in an increased risk of morbidity and mortal- ity, as well.5, 6 Appropriate early treat- of stay and rates of morbidity and mor- tality.7, 8, 9 PCR-based formats for MRSA/S. aureus identifi cation have reduced the time of diagnosis from 24 to 48 hours using standard microbiological approaches to 1 to 2 hours, shortened length of stay, and reduced treatment Recently described real-time Sometimes the Simplest Answer is the Best… P eople are often quick to look for high tech solutions. But very often the smarter answer is the one you've been able to depend on for years. Such as the MICROSAFE® Tube: easy to use, accurate, dependable, and cost effective: the perfect solution for fingerstick blood sampling. • Collection and dispensing from a single plastic tube. • Fills by capillary action to a preset volume. • Dispense by pinching the unfilled portion of the tube. • Available in volumes from 5µl to 80µl. • For InVitro use. • and ISO 13485:003 certified. Ordering information: 001-215-364-5582 n Fax: 001-215-364-7335 e-mail: sales@safe-tecllc.com n Web Site: www.safe-tecllc.com 142 Railroad Drive n Ivyland, PA 18974 Esdoennlaan 13 n 3951 DB Maarn n The Netherlands partner 4U B.V. 22 IVD TECHNOLOGY | NOVEMBER/DECEMBER 2012 costs because of more-rapid initiation of appropriate antibiotic treatment.10 However, these tests do not provide information about coagulase-negative staphylococci, with their presence implied only by a negative test result for gram-positive cocci in clusters of positive blood culture. Because up to 90% of coagulase-negative staphylo- cocci are methicillin-resistant, clini- cians typically treat suspected blood stream infections with vancomycin. However, several reports have shown that vancomycin was less eff ective than beta-lactam antibiotics for treatment of S. aureus infections and its misuse could potentially lead to resistance. Rapid determination of mecA gene status for coagulase-negative staphylo- cocci may initiate switching of meth- icillin-sensitive infection treatment from vancomycin to beta-lactam drugs; early clinical studies have observed a positive eff ect on patient outcome.11 Appropriate management of infec- tion also includes determining when treatment is not required. It has been reported that contaminating bacteria account for 2.5% of all blood cultures on average, or roughly 25% of all posi- tive blood cultures, with 70 to 80% of these cases being caused by coagulase negative Staphylococcus.12 of these cases may be unnecessary and lead to longer lengths of stay and higher treatment costs.13 Treatment distinguish contaminants, one method ivdtechnology.com In order to

Articles in this issue

Links on this page

Archives of this issue

view archives of IVDT_In Vitro Diagnostics Technology - IVD Technology, November/December 2012